April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Laura Dawson Chosen as ASTRO President-Elect
July 26th 2019Laura Dawson, MD, FRCPC, FASTRO, has been selected as the president-elect of the American Society for Radiation Oncology and will begin her term at the society’s 61st Annual Meeting, which is being held in Chicago, Illinois on September 15-18.
Read More
The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial Cancer
July 17th 2019Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab in patients with microsatellite instability–high and microsatellite stable endometrial cancer.
Watch
Phase III PRIMA Trial Shows PFS Benefit With Niraparib as First-Line Maintenance in Ovarian Cancer
July 15th 2019In the phase III PRIMA trial, niraparib demonstrated a benefit in progression-free survival compared with placebo when used as maintenance therapy following platinum-based chemotherapy for patients with ovarian cancer treated in the first line. The PFS benefit was found to be statistically significant, regardless of patients’ biomarker status, meeting the primary endpoint of the trial.
Read More
Study of SM-88 Shows Promising Results in Advanced Pancreatic Cancer
July 12th 2019The investigational agent SM-88 demonstrated promising survival in the phase II TYME-88-Panc study in patients with advanced pancreatic cancer.<sup>1,2</sup> The oral modified dysfunctional tyrosine induced a median overall survival of 6.4 months in patients.<br />
Read More
ACCC Collaborates to Launch Care Improvement Initiative for Patients With Ovarian Cancer
July 12th 2019The Association of Community Cancer Centers has launched the Barriers to Quality Care in Ovarian Cancer project, a collaboration with AstraZeneca, Merck, and partners including the Association for Molecular Pathology, the National Society of Genetic Counselors, and the Society of Gynecologic Oncology. The project aims to understand the key issues associated with ovarian cancer care and provide guidance to help cancer centers implement better care for patients diagnosed with epithelial ovarian cancer.
Read More
Bevacizumab Biosimilar Enjoys Broad Approvals; Is Ovarian Cancer Indication Looming?
July 3rd 2019Bradley J. Monk, MD, noted the FDA’s approval of the biosimilar agent bevacizumab-awwb across multiple indications including metastatic colorectal cancer, non–small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer, but he wondered aloud why ovarian cancer was not on the list.
Read More
Explaining Synergy in the Olaparib/Neratinib Combination for Uterine Serous Carcinomas
July 2nd 2019Ghanshyam Yadav, MD, a first-year resident in Obstetrics Gynecology & Reproductive Services, Baylor College of Medicine, talks through the results of a preclinical trial that found synergy in the combination of the PARP inhibitor olaparib and the pan-HER tyrosine kinase inhibitor neratinib for uterine serous cancers that overexpress HER2.
Watch
A Look Back at FDA News from June 2019
July 1st 2019In June 2019, the FDA approved a number of agents many fields, including diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, small cell lung cancer, gastroenteropancreatic neuroendocrine tumors, and multiple myeloma. The FDA also approved the fifth biosimilar for trastuzumab and another biosimilar for bevacizumab across several indications.
Read More
Phase III Shows Benefit With Olaparib in Platinum-Sensitive BRCA+ Relapsed Ovarian Cancer
June 30th 2019In an interview with <em>Targeted Oncology, </em>Richard T. Penson, MD, discussed the significance of the findings recently presented for the SOLO3 trial in patients with platinum-sensitive, relapsed <em>BRCA-</em>positive ovarian cancer.
Read More